Collegium’s Pain Sales Fall 18% As ADHD Growth Leaves Earnings Behind

Jornay PM sales grew 24%, but operating expenses rose faster and Collegium kept its annual forecasts unchanged.

Share
Collegium’s Pain Sales Fall 18% As ADHD Growth Leaves Earnings Behind

Collegium Pharmaceutical, which sells prescription ADHD and pain medicines, reported an 18% decline in third-quarter pain sales Thursday, even as its expanding ADHD business helped revenue reach a record $216.3 million. Revenue rose 3% from $209.4 million a year earlier, but both reported and adjusted earnings fell, according to the earnings release accompanying its SEC filing.

Higher Sales, Lower Earnings

Operating expenses reached $96.7 million, a 44% increase from $67.1 million a year earlier. Even after Collegium’s adjustments, expenses rose 25%, to $69.4 million from $55.7 million.

The earnings release put net income at $21.8 million, compared with $31.5 million a year earlier. Diluted earnings per share dropped from $0.84 to $0.60; adjusted earnings were $1.96 per share on $75.2 million of net income, versus $2.25 and $87.3 million.

Adjusted earnings before interest, taxes, depreciation and amortization fell 9%, to $121.6 million from $133.0 million. COLL shares fell about 3% to $24.40 in Friday trading.

ADHD Expands, Pain Contracts

Jornay PM delivered $51.9 million in sales, up 24% year-over-year. Prescription volume rose 16%, while its prescriber base grew 19% to nearly 33,000, a record for the medicine.

Vikram Karnani, Collegium’s president and chief executive officer, attributed ADHD demand to “expanded commercial efforts heading into the back-to-school season.” Azstarys added $26.5 million in its first full quarter under Collegium ownership, with prescriptions increasing nearly 2% year-over-year after declining in 2025.

The ADHD expansion rests on acquisitions. The 2024 Ironshore purchase brought Jornay PM and a sales team focused on neuropsychiatry and pediatrics; Collegium added Azstarys in May 2026, using its existing commercial infrastructure. Chief Financial Officer Colleen Tupper said ADHD now accounts for more than 36% of revenue.

Pain medicines still generated $138.0 million. Belbuca sales slipped 1% to $57.7 million, Xtampza ER fell 9% to $45.8 million, and the Nucynta franchise dropped 44% to $30.8 million. Nucynta’s total included $4.2 million from Hikma Pharmaceuticals USA for authorized generic versions of Nucynta and Nucynta ER.

Forecasts Hold, Buyback Settlement Ahead

Collegium retained its 2026 revenue outlook of $825 million to $855 million, including $190 million to $200 million for Jornay PM and $65 million to $75 million for Azstarys. Its forecast for adjusted earnings before interest, taxes, depreciation and amortization also stayed at $445 million to $470 million.

Operations generated $86.5 million in cash during the quarter. Collegium ended the period with $144.8 million in cash, cash equivalents and marketable securities.

Capital returns remain part of the plan. Collegium’s earnings presentation describes a $50 million buyback announced during the third quarter, structured as an accelerated share repurchase.

Collegium expects final settlement of that previously announced repurchase in the fourth quarter of 2026.

Sources

More on Collegium Pharmaceutical

All Collegium Pharmaceutical (COLL) coverage →